| Dose |
55Gy |
52.5Gy |
| Adjuvant Hormones |
2 yrs |
None |
None |
| |
584 |
|
| Total |
147 |
437 |
301 |
| Years |
2001 - 2005 |
1995 – 2001 |
| Age |
|
|
|
| Mean |
66.6 |
67.4 |
67.7 |
| Median |
68 |
68 |
69 |
| Range |
51 – 78 |
49 – 80 |
47 – 80 |
| Stage (N0 M0) |
|
|
|
| T1 |
21 (14.3%) |
130 (29.8%) |
53 (17.7%) |
| T2 |
64 (43.5%) |
244 (55.8%) |
149 (49.3%) |
| T3 |
62 (42.2%) |
63 (14.4%) |
99 (33.0%) |
| Gleason |
|
|
|
| 4 |
0 |
3 (0.7%) |
27 (9.0%) |
| 5 |
0 |
14 (3.2%) |
43 (14.3%) |
| 6 |
3 (2.0%) |
195 (44.6%) |
88 (29.3%) |
| 7 |
47 (32.0%) |
210 (48.1%) |
88 (29.3%) |
| 8 |
56 (38.1%) |
10 (2.3%) |
37 (12.3%) |
| 9 |
39 (26.5%) |
5 (1.1%) |
16 (5.3%) |
| 10 |
2 (1.4%) |
0 |
2 0.7%) |
| Presenting PSA |
|
|
|
| <= 10 |
29 (19.7%) |
165 (37.8%) |
68 (22.7%) |
| >10 <= 20 |
34 (23.1%) |
165 (37.8%) |
100 (33.3%) |
| >20 <=50 |
60 (40.8%) |
102 (23.3%) |
96 (32.0%) |
| > 50 |
24 (16.3%) |
5 (1.1%) |
36 (12.0%) |
| NK |
|
|
1 |
| Median |
24.8 |
12.0 |
17.9 |
| Surgery |
|
|
|
| TURP |
11 (7.5%) |
29 (6.6%) |
75 (25.0%) |
| Biopsy only |
136 |
408 |
226 |
| Prognostic group |
|
|
|
| Good |
0 |
78 (17.8%) |
37 (12.3%) |
| Intermediate |
22 (15.0%) |
189 (43.3%) |
103 (34.3%) |
| Poor |
125 (85.0%) |
170 (38.9) |
160 (53.3%) |
| NK |
|
|
12 |
|
